| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | |
|---|---|---|---|---|
| Restructuring charges | 0 | - | - | |
| Operating loss | -26,244 | - | - | |
| Foreign currency gain/(loss), net | 1,934 | - | - | |
| Other income, net | 770 | - | - | |
| Benefit from r&d credit | 2,583 | - | - | |
| Contracted development costs | - | 12,232 | 14,673 | |
| Loss before income tax expense | -20,957 | - | - | |
| Personnel research and development costs | - | 4,479 | 5,556 | |
| Income tax expense | 1 | - | - | |
| Net loss | -20,958 | -27,354 | -28,530 | |
| Earnings per share, basic | -0.15 | -0.19 | -0.2 | |
| Earnings per share, diluted | -0.15 | -0.19 | -0.2 | |
| Weighted average number of shares outstanding, basic | 141,701,848 | 141,696,047 | 141,678,734 | |
| Weighted average number of shares outstanding, diluted | 141,701,848 | 141,696,047 | 141,678,734 | |
Silence Therapeutics plc (SLN)
Silence Therapeutics plc (SLN)